Civitas raises $38M to advance drug for Parkinson's complication

09/12/2013 | American City Business Journals

A Series B funding round has brought in $38 million for Chelsea, Mass.-based biotech firm Civitas Therapeutics. Civitas plans to use the money to support clinical development of its experimental drug CVT-301, which is under development for debilitating motor fluctuations in Parkinson's disease patients.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY